论文部分内容阅读
目的探讨游离HCV Core Ag阳性患者组和抗-HCV阳性病程1年以上患者组经治疗后不同基因型EVR。方法筛选有危险因素人群游离HCV Core Ag阳性35例和抗-HCV阳性病程在1年以上患者40例,通过检查结果确定治疗方案,比较EVR。结果血清学分型1型两组患者EVR有显著性差异(P<0.01),2型Fisher精确检验精确Sig.(单侧)<0.05,有统计学意义。结论游离HCV Core Ag检测对丙肝早期治疗有促进作用。
Objective To investigate the genotypes of different genotypes in patients with HCV Core Ag positive and those with anti-HCV positive disease more than 1 year after treatment. Methods Thirty-five patients with positive HCV Core Ag and 40 patients with anti-HCV positive disease over one year were screened in the population with risk factors. The treatment regimens were determined by the test results and the EVR was compared. Results Serum type 1 type 2 patients had significant difference in EVR (P <0.01), type 2 Fisher exact test exact Sig. (Unilateral) <0.05, with statistical significance. Conclusion The detection of free HCV Core Ag can promote the early treatment of hepatitis C.